{
    "paper_id": "PMC7108343",
    "metadata": {
        "title": "Acute exacerbations of chronic obstructive pulmonary disease: treatment and prevention",
        "authors": [
            {
                "first": "Terence",
                "middle": [],
                "last": "Seemungal",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jadwiga",
                "middle": [
                    "A."
                ],
                "last": "Wedzicha",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\nTable 1 lists the common microbial agents associated with exacerbations of COPD. Respiratory viruses have been shown to cause prolonged exacerbations and are associated with increased lower airway inflammation. There is evidence that chronic infection or prolonged carriage after acute infection may occur with adenovirus and respiratory syncytial virus.",
            "cite_spans": [],
            "section": "Aetiology",
            "ref_spans": [
                {
                    "start": 1,
                    "end": 8,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "The role of bacteria is complex. The common bacteria identified in COPD are:",
            "cite_spans": [],
            "section": "Aetiology",
            "ref_spans": []
        },
        {
            "text": "\n\u2022\nStreptococcus pneumoniae\n\u2022\nHaemophilus influenzae\n\u2022\nMoraxella catarrhalis\n\n",
            "cite_spans": [],
            "section": "Aetiology",
            "ref_spans": []
        },
        {
            "text": "In severe COPD, gram-negative organisms are also of importance, especially Pseudomonas aeruginosa. Patients with bacteria in their sputum are more likely to suffer exacerbations and experience prolonged recovery and greater severity. Many studies have shown no change in bacterial species during exacerbations, though changes may be seen in the bacterial strains obtained from patients.",
            "cite_spans": [],
            "section": "Aetiology",
            "ref_spans": []
        },
        {
            "text": "COPD has four principal symptoms:",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "\n\u2022dyspnoea\u2022cough\u2022sputum volume\u2022sputum purulence.\n",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "The diagnosis of an acute exacerbation is based on an acute sustained deterioration in sputum purulence and increased volume, and dyspnoea.1, 2 These may be associated with symptoms of an upper respiratory tract infection (cold or sore throat).",
            "cite_spans": [
                {
                    "start": 139,
                    "end": 140,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 142,
                    "end": 143,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "The differential diagnosis includes:",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "\n\u2022pneumonia\u2022pulmonary embolism\u2022pneumothorax\u2022pleural effusion\u2022cardiac disease (congestive cardiac failure, arrhythmias)\u2022rib fracture\u2022inappropriate use of sedatives.\n",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "The chest radiograph is not required for the diagnosis of a COPD exacerbation but it is useful in the establishment of many of the above. Briefly, patchy mainly air space shadowing chiefly in a lobar distribution is indicative of a community-acquired pneumonia, unilateral absence of lung markings at the periphery of the lung field together with a visible lung border in the apex indicates a pneumothorax, bat\u2019s wing shadowing with cardiomegaly indicates congestive cardiac failure. Where the chest radiograph is equivocal, brain-type natriuretic peptide, a useful marker of cardiac failure, is indicated. A rib fracture may be seen on a radiograph to be coincident with an area of localized chest wall tenderness.",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "The differentiation between a pulmonary embolism and a COPD exacerbation may always be difficult but is more so in severe COPD. In severe COPD, the chest radiograph may show little more than hyperexpansion with large pulmonary arteries. The ECG shows a right ventricular strain pattern in both conditions. However, a low systolic blood pressure and an inability to elevate the arterial oxygen tension above 8 kPa (60 mmHg) in spite of use of high flow oxygen favours an embolic phenomenon.",
            "cite_spans": [],
            "section": "Diagnosis and differential diagnosis",
            "ref_spans": []
        },
        {
            "text": "A staging system for COPD exacerbations has not yet been agreed. However, it is generally accepted that the following features in the history are suggestive of a worse prognosis:",
            "cite_spans": [],
            "section": "Severity",
            "ref_spans": []
        },
        {
            "text": "\n\u2022severity of underlying COPD\u2022history of more than 3 exacerbations per year or 1 or more previous hospitalizations for COPD-related illness in the previous year\u2022presence of comorbidities.1\n\n",
            "cite_spans": [
                {
                    "start": 187,
                    "end": 188,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Severity",
            "ref_spans": []
        },
        {
            "text": "Signs of severity are use of accessory muscles, haemodynamic instability, worsening or new-onset central cyanosis, peripheral oedema, signs of cor pulmonale and, importantly, acute confusion.",
            "cite_spans": [],
            "section": "Severity",
            "ref_spans": []
        },
        {
            "text": "Regular assessment is required after initiation of therapy in the community. Referral to hospital should be considered when there is no improvement or the patient deteriorates. Referral should also be considered for those with a severe exacerbation (see above) and when any of the following criteria apply:",
            "cite_spans": [],
            "section": "Referral to tertiary centre ::: Community management",
            "ref_spans": []
        },
        {
            "text": "\n\u2022presence of a new cardiac arrhythmia\u2022insufficient home support\u2022elderly patient\u2022uncertain diagnosis.\n",
            "cite_spans": [],
            "section": "Referral to tertiary centre ::: Community management",
            "ref_spans": []
        },
        {
            "text": "\nInitial management \u2013 rapid management of these patients may prevent complications requiring intensive care. Airway, breathing and circulation should be assessed immediately on arrival. Controlled oxygen should be given via a Venturi mask to patients with an arterial oxygen saturation (SaO2) of less than 90% or an arterial partial pressure of oxygen (PaO2) of less than 8 kPa. Because carbon dioxide retention occurs insidiously with rising PaO2 in these patients, the aim is to maintain SaO2 at 92\u201394%. Arterial blood gases should be rechecked at 30 minutes to assess the pH. While this is performed, a postero-anterior chest radiograph and ECG are requested. Spirometry may be helpful; a forced expiratory volume in 1 second (FEV1) of less than 1.0 litre is considered an index of a severe exacerbation. Haemoglobin concentration and blood potassium levels should be measured.",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "While the patient is in the A&E department, nebulized bronchodilator therapy with both \u03b22-agonists and anticholinergic agents should be started, oral corticosteroids administered and aminophylline considered. Most studies of intravenous aminophylline have demonstrated only minor benefits in COPD exacerbations, though the sample size in these studies has been relatively small. Antibiotics may be prescribed as above.",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "\nFurther treatment \u2013 early discharge from the A&E department with out-patient follow-up may be considered in patients who suffer an uncomplicated exacerbation without severe symptoms, in those with no respiratory failure, and when adequate home and community nurse support is available. Otherwise, the patient should be admitted to the ward.",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "Non-invasive positive-pressure ventilation (NIV) should be considered in patients with an arterial pH of less than 7.35 on maximal medical therapy. NIV has been shown to improve mortality and reduce the need for intubation and duration of hospital stay in these patients. In the absence of NIV or delay in its application, doxapram (a respiratory stimulant that may be helpful in acute respiratory failure) may be considered, with cardiac monitoring. A Cochrane Review suggests that doxapram \u2018may improve blood gas exchange in the short term\u2019.5 Patient monitoring is crucial at this stage because mortality increases once the pH declines below 7.26; ideally, patients should be cared for in a high-dependency unit. Referral to an intensive care unit is required for those who deteriorate further with increasing hypoxia and worsening pH.",
            "cite_spans": [
                {
                    "start": 543,
                    "end": 544,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "\nIn-hospital management: continued monitoring of arterial blood gases is required while respiratory failure is still present, and attention to fluid status is vital. In-hospital treatment of acute COPD exacerbations with antibiotics is associated with reduced treatment failures and mortality. Fluid management and fluid balance are essential. Deep vein thrombosis prophylaxis is considered in the immobilized, polycythaemic or dehydrated patient. Physiotherapy to induce sputum clearance is recommended.",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "As the patient\u2019s symptoms improve, medication should be tapered back to the levels used before admission. Spirometry is used to confirm the severity of disease before discharge. Serial peak flow measurements are not helpful during exacerbations; they may vary little, and the median decrease at exacerbation is small.",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "\nDischarge \u2013 the median duration of stay in hospital is about 1 week. Discharge is considered when:",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "\n\u2022the patient has been clinically stable for 24 hours, and understands how to administer his or her treatment\u2022home and follow-up care arrangements are completed\u2022the patient, family and physician are confident that the patient can manage successfully at home.\n",
            "cite_spans": [],
            "section": "Accident and emergency department ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "Hospital assessment at 4\u20136 weeks is recommended for all patients, to consider their coping skills and measure FEV1. About 75% of patients have fully recovered by this time. Inhaler technique and the long-term need for nebulizers are assessed, and the patient may be given advice on how to recognize symptoms of a COPD exacerbation.6 There is evidence that an appropriate home-care package with specialist nurse advice in the outpatient setting reduces readmission.1, 2\n",
            "cite_spans": [
                {
                    "start": 331,
                    "end": 332,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 464,
                    "end": 465,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 467,
                    "end": 468,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Out-patient follow-up ::: Hospital management",
            "ref_spans": []
        },
        {
            "text": "Frequent COPD exacerbations are associated with poor quality-of-life scores, greater levels of hospitalization, greater health burden, more rapid decline in lung function and greater airway inflammation.\nFigure 1 shows the significant proportion of the quality-of-life scores accounted for an exacerbation frequency of greater than 3 per year. Measures to reduce the risk of exacerbation are therefore important. Viral infections are important possible therapeutic targets, though there are currently few appropriate interventions. Influenza vaccine is strongly recommended for all COPD patients, and patients are advised to avoid upper respiratory tract infections. The pneumococcal vaccine, though recommended for patients with chronic lung disease, has been shown to be effective only in some subsets of COPD patients in randomized controlled studies. Systematic reviews have not supported the use of oral bacterial extracts as immunostimulants in COPD.",
            "cite_spans": [],
            "section": "Prevention of exacerbations",
            "ref_spans": [
                {
                    "start": 204,
                    "end": 212,
                    "mention": "Figure 1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Both inhaled corticosteroids and long-acting anticholinergic agents have been shown to reduce the frequency of exacerbations. Mucolytic agents are used in several countires world-wide but the current weight of evidence does not support their use in exacerbation prevention. Several non-pharmacologica therapies have been shown to be useful in exacerbation prevention and, of these, pulmonary rehabilitation has received much attention. Both long-term oxygen therapy and non-invasive ventilation reduce COPD-related hospitalization.Practice points\n\u2022Acute exacerbations of COPD are defined by symptoms\u2022Cardiac failure is an important differential diagnosis\u2022Antibiotics are indicated when there are sputum changes\u2022Oral steroids hasten recovery and decrease the risk of relapse\u2022Patients with acute exacerbations treated in the emergency department must be treated proactively to prevent rapid deterioration\n\n",
            "cite_spans": [],
            "section": "Prevention of exacerbations",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Micro-organisms associated with COPD exacerbations\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: The proportion of the variability in quality of life measured by the total St George's Respiratory questionnaire total score explained by variables explored in the London COPD Study",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary",
            "authors": [
                {
                    "first": "K.F.",
                    "middle": [],
                    "last": "Rabe",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Hurd",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Anzueto",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Am J Respir Crit Care Med",
            "volume": "176",
            "issn": "",
            "pages": "532-555",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "International Primary Care Respiratory Group (IPCRG) guidelines: management of chronic obstructive pulmonary disease (COPD)",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Bellamy",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Bouchard",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Henrichsen",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Prim Care Respir J",
            "volume": "15",
            "issn": "",
            "pages": "48-57",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Davies",
                    "suffix": ""
                },
                {
                    "first": "R.M.",
                    "middle": [],
                    "last": "Angus",
                    "suffix": ""
                },
                {
                    "first": "P.M.A.",
                    "middle": [],
                    "last": "Calverley",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Lancet",
            "volume": "354",
            "issn": "",
            "pages": "456-460",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "D.E.",
                    "middle": [],
                    "last": "Niewoehner",
                    "suffix": ""
                },
                {
                    "first": "M.L.",
                    "middle": [],
                    "last": "Erbland",
                    "suffix": ""
                },
                {
                    "first": "R.H.",
                    "middle": [],
                    "last": "Deupree",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "N Engl J Med",
            "volume": "340",
            "issn": "",
            "pages": "1941-1947",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Greenstone",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Cochrane Database Syst Rev",
            "volume": "2",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease",
            "authors": [
                {
                    "first": "T.A.R.",
                    "middle": [],
                    "last": "Seemungal",
                    "suffix": ""
                },
                {
                    "first": "G.C.",
                    "middle": [],
                    "last": "Donaldson",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Bhowmik",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Am J Respir Crit Care Med",
            "volume": "161",
            "issn": "",
            "pages": "1608-1613",
            "other_ids": {
                "DOI": []
            }
        }
    }
}